BR112017007708A2 - composto macrocíclicos, uso de um composto macrocíclicos, método para tratamento, unidade de dose, composição farmacêutica e método para tratar câncer em um paciente - Google Patents

composto macrocíclicos, uso de um composto macrocíclicos, método para tratamento, unidade de dose, composição farmacêutica e método para tratar câncer em um paciente

Info

Publication number
BR112017007708A2
BR112017007708A2 BR112017007708A BR112017007708A BR112017007708A2 BR 112017007708 A2 BR112017007708 A2 BR 112017007708A2 BR 112017007708 A BR112017007708 A BR 112017007708A BR 112017007708 A BR112017007708 A BR 112017007708A BR 112017007708 A2 BR112017007708 A2 BR 112017007708A2
Authority
BR
Brazil
Prior art keywords
macrocyclic compound
patient
treatment
pharmaceutical composition
unit dose
Prior art date
Application number
BR112017007708A
Other languages
English (en)
Other versions
BR112017007708A8 (pt
BR112017007708B1 (pt
BR112017007708B8 (pt
Inventor
Joseph Breslin Henry
Gilad Oren
Original Assignee
Atrin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atrin Pharmaceuticals LLC filed Critical Atrin Pharmaceuticals LLC
Publication of BR112017007708A8 publication Critical patent/BR112017007708A8/pt
Publication of BR112017007708A2 publication Critical patent/BR112017007708A2/pt
Publication of BR112017007708B1 publication Critical patent/BR112017007708B1/pt
Publication of BR112017007708B8 publication Critical patent/BR112017007708B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Abstract

um composto macrocíclico tendo a estrutura da fórmula (a), onde cada um de r1 e r2 é independentemente (i) um anel aromático monocíclico de 5-6 membros contendo de 0-4 heteroátomos selecionados independentemente de nitrogênio, oxigênio, ou enxofre; ou (ii) um anel aromático bicíclico de 8-10 membros contendo de 0-6 heteroátomos selecionados, independentemente, de nitrogênio, oxigênio, o enxofre. cada r1 e r2 podem, independentemente, ser substituídos por 0, 1, 2, 3, ou 4 substituintes. z1 representa uma ligação covalente, um átomo de, ou um grupo funcional compreendendo um agrupamento de átomos, onde o grupamento de átomos inclui pelo menos um heteroátomo selecionado a partir do grupo consistindo de n, o, p, e s.
BR112017007708A 2014-10-13 2015-10-13 Composto macrocíclico e composição farmacêutica BR112017007708B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462063176P 2014-10-13 2014-10-13
US62/063,176 2014-10-13
US201562104274P 2015-01-16 2015-01-16
US62/104,274 2015-01-16
PCT/US2015/055317 WO2016061097A1 (en) 2014-10-13 2015-10-13 Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors

Publications (4)

Publication Number Publication Date
BR112017007708A8 BR112017007708A8 (pt) 2017-12-19
BR112017007708A2 true BR112017007708A2 (pt) 2017-12-19
BR112017007708B1 BR112017007708B1 (pt) 2023-07-25
BR112017007708B8 BR112017007708B8 (pt) 2023-10-24

Family

ID=55654998

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007708A BR112017007708B8 (pt) 2014-10-13 2015-10-13 Composto macrocíclico e composição farmacêutica

Country Status (12)

Country Link
US (3) US9663535B2 (pt)
EP (1) EP3207031B1 (pt)
JP (1) JP6678679B2 (pt)
KR (1) KR102569226B1 (pt)
CN (1) CN107108527B (pt)
AU (1) AU2015333738B2 (pt)
BR (1) BR112017007708B8 (pt)
CA (1) CA2963973C (pt)
ES (1) ES2879441T3 (pt)
IL (1) IL251595B (pt)
MX (1) MX2017004515A (pt)
WO (1) WO2016061097A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108527B (zh) 2014-10-13 2022-08-02 阿特林制药有限责任公司 共济失调性毛细血管扩张和Rad3相关的(ATR)蛋白激酶抑制剂
WO2017180723A1 (en) * 2016-04-12 2017-10-19 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use
EP3630116B1 (en) 2017-05-26 2024-05-01 The Board Of Regents Of The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
MX2020000386A (es) 2017-07-13 2020-08-06 Univ Texas Inhibidores heterociclicos de la cinasa atr.
US10800774B2 (en) 2017-08-17 2020-10-13 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
US11267809B2 (en) 2017-09-14 2022-03-08 The Board Of Trustees Of The Leland Stanford Junior University BAF complex modulating compounds and methods of using the same
JP7341156B2 (ja) 2018-03-16 2023-09-08 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
CN110357905B (zh) * 2018-03-26 2021-10-01 武汉誉祥医药科技有限公司 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途
CN110950890B (zh) * 2018-09-27 2022-07-01 北京赛林泰医药技术有限公司 取代的咪唑并[4,5-c]喹啉大环化合物作为多靶点激酶抑制剂
US20240025899A1 (en) 2020-10-16 2024-01-25 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof
WO2023201320A1 (en) 2022-04-14 2023-10-19 Atrin Pharmaceuticals LLC Atr inhibitors
WO2023242302A1 (en) 2022-06-15 2023-12-21 Astrazeneca Ab Combination therapy for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084341B (en) * 2003-02-26 2008-03-25 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
US7163939B2 (en) * 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
SI3354650T1 (sl) * 2008-12-19 2022-06-30 Vertex Pharmaceuticals Incorporated Spojine, uporabne kot zaviralci ATR kinaze
EP2569287B1 (en) 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2012125603A1 (en) * 2011-03-16 2012-09-20 Cephalon, Inc. Macrocyclic compounds as alk, fak and jak2 inhibitors
ES2621220T3 (es) 2012-03-06 2017-07-03 Pfizer Inc. Derivados macrocíclicos para el tratamiento de enfermedades proliferativas
NZ630901A (en) * 2012-03-17 2015-09-25 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
CN107108527B (zh) 2014-10-13 2022-08-02 阿特林制药有限责任公司 共济失调性毛细血管扩张和Rad3相关的(ATR)蛋白激酶抑制剂

Also Published As

Publication number Publication date
US20160102104A1 (en) 2016-04-14
EP3207031A4 (en) 2018-02-14
CN107108527B (zh) 2022-08-02
US20170226130A1 (en) 2017-08-10
US10196405B2 (en) 2019-02-05
JP6678679B2 (ja) 2020-04-08
MX2017004515A (es) 2017-10-31
EP3207031B1 (en) 2021-04-14
KR20170082532A (ko) 2017-07-14
EP3207031A1 (en) 2017-08-23
IL251595A0 (en) 2017-06-29
US9663535B2 (en) 2017-05-30
BR112017007708A8 (pt) 2017-12-19
US20180230168A1 (en) 2018-08-16
BR112017007708B1 (pt) 2023-07-25
US9981989B2 (en) 2018-05-29
AU2015333738A1 (en) 2017-05-04
AU2015333738B2 (en) 2020-03-26
ES2879441T3 (es) 2021-11-22
JP2017531041A (ja) 2017-10-19
BR112017007708B8 (pt) 2023-10-24
WO2016061097A1 (en) 2016-04-21
IL251595B (en) 2022-04-01
CA2963973A1 (en) 2016-04-21
CN107108527A (zh) 2017-08-29
KR102569226B1 (ko) 2023-08-22
CA2963973C (en) 2023-01-10

Similar Documents

Publication Publication Date Title
BR112017007708A2 (pt) composto macrocíclicos, uso de um composto macrocíclicos, método para tratamento, unidade de dose, composição farmacêutica e método para tratar câncer em um paciente
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
MX2020007485A (es) Compuestos antiproliferativos y metodos de uso de los mismos.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
BR112018007876A2 (pt) derivado de benzofurano, método de preparação do mesmo e uso do mesmo na medicina
BR112017026025A2 (pt) composições que compreendem um inibidor de stemness de câncer e um agente imunoterápico para uso no tratamento de câncer
EA201890159A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКОГО ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ С ПОМОЩЬЮ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
CY1122892T1 (el) Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
BR112016016870A8 (pt) derivados de icariina, seus usos, e composição farmacêutica
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
MX2021001612A (es) Compuestos utiles en terapia del vih.
MX2018006953A (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 241/04

Ipc: A61K 31/4985 (2006.01), A61K 31/5377 (2006.01), A6

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2015, OBSERVADAS AS CONDICOES LEGAIS

B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFIQUE-SE PARA CORRECAO DE ERROS DE DIGITACAO APONTADOS PELA REQUERENTE.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2742 DE 25/07/2023, QUANTO AO QUADRO REIVINDICATORIO.